Wen-Pin Su

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 162 citations · Full text

Urology, Oncology, Metastatic Urothelial Carcinoma +7

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 69 citations · Full text

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +7

Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.

Thomas Powles, Juergen E. Gschwend, Yohann Loriot et al. · Journal of Clinical Oncology · 2017 · 47 citations

Cisplatin-ineligible Pts, Tps4590 Background, Urology +13